Melphalan and whole-blood stem cell reinfusion in castration-resistant prostate cancer (CRPC): A phase I/II study.

被引：0
|
作者：
Shamash, J.
Jacob, J.
Powles, T.
Agrawal, S.
Mutsvangwa, K.
Saunders, N.
Wilson, P.
Stebbing, J.
机构：
[1] St Bartholomews Hosp, London, England
[2] Univ London Imperial Coll Sci Technol & Med, London, England
[3] St Barthlomews Hosp, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.2573
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2573
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Whole Blood Stem Cell Reinfusion and Escalated Dose Melphalan in Castration-Resistant Prostate Cancer: A Phase 1 Study
    Shamash, Jonathan
    Jacob, Jimmy
    Agrawal, Samir
    Powles, Thomas
    Mutsvangwa, Katherine
    Wilson, Peter
    Stebbing, Justin
    CLINICAL CANCER RESEARCH, 2012, 18 (08) : 2352 - 2359
  • [2] Docetaxel and curcuminoids (CCM) combination in patients with castration-resistant prostate cancer (CRPC): A phase II study.
    Mahammedi, Hakim
    Pouget, Melanie
    Planchat, Eloise
    Cure, Herve
    Durando, Xavier
    Bayet-Robert, Mathilde
    Van-Praagh, Isabelle
    Atger, Marc
    Guy, Laurent
    Abrial, Catherine
    Chollet, Philippe J. M.
    Eymard, Jean-Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] A phase I/II study of enzalutamide in combination with indomethacin in men with castration-resistant prostate cancer (CRPC)
    Leibrandt, Ryan
    Ullah, Ayman Teeham
    Verma, Rashmi
    Gao, Allen
    Lara, Primo N., Jr.
    Pan, Chong-xian
    Parikh, Mamta
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] A PHASE II PROSPECTIVE STUDY OF KETOCONAZOLE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS (CRPC)
    Verzoni, E.
    Bajetta, E.
    Giganti, M. O.
    Guadalupi, V.
    Capone, F.
    Donegani, S.
    Nicolai, N.
    Salvioni, R.
    Valdagni, R.
    Procopio, G.
    ANNALS OF ONCOLOGY, 2010, 21 : 278 - 278
  • [5] A PHASE II PROSPECTIVE STUDY OF KETOCONAZOLE IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS
    Guadalupi, V.
    Giganti, M. O.
    Testa, I.
    Villa, S.
    Nicolai, N.
    Biasoni, D.
    Salvioni, R.
    Valdagni, R.
    Bajetta, E.
    Procopio, G.
    ANTICANCER RESEARCH, 2010, 30 (04) : 1536 - 1536
  • [6] Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC)
    Scher, H. I.
    Beer, T. M.
    Higano, C. S.
    Taplin, M.
    Efstathiou, E.
    Anand, A.
    Hung, D.
    Hirmand, M.
    Fleisher, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] Phase I/II study of MDV3100 in patients (pts) with progressive castration-resistant prostate cancer (CRPC)
    Scher, H. I.
    Beer, T. M.
    Higano, C. S.
    Danila, D. C.
    Montgomery, B.
    Shelkey, J.
    Hirmand, M.
    Hung, D.
    Sawyers, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] CASTRATION-RESISTANT PROSTATE CANCER (CRPC): A UK EPIDEMIOLOGY STUDY
    Morgan, C.
    McEwan, P.
    Chamberlain, G.
    Cabrera, C.
    Parry, D.
    VALUE IN HEALTH, 2010, 13 (03) : A26 - A26
  • [9] Dependence of Castration-Resistant Prostate Cancer (CRPC) Stem Cells on CRPC-Associated Fibroblasts
    Adisetiyo, Helty
    Liang, Mengmeng
    Liao, Chun-Peng
    Jeong, Joseph H.
    Cohen, Michael B.
    Roy-Burman, Pradip
    Frenkel, Baruch
    JOURNAL OF CELLULAR PHYSIOLOGY, 2014, 229 (09) : 1170 - 1176
  • [10] A phase Ib/II trial of indomethacin and enzalutamide to treat castration-resistant prostate cancer (CRPC).
    Pan, Chong-xian
    Lara, Primo
    Evans, Christopher P.
    Parikh, Mamta
    White, Ralph de Vere
    Dall'era, Marc
    Liu, Chengfei
    Robles, Daniel
    Gao, Allen
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
12345